December 20, 2017 10:10 AM ESTUpdated May 26, 08:50 PM
Financing
Startups
Cell/Gene Tx

In gene ther­a­py's sec­ond big win this week, Or­chard nabs $110M Se­ries B

Brittany Meiling

Lon­don start­up Or­chard Ther­a­peu­tics is join­ing the ranks of com­mer­cial-stage gene ther­a­py com­pa­nies with a new $110 mil­lion Se­ries B round to take its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times